Locus Cell Co., Ltd. (TPEX: 6891)

Market Cap	5.91B
Revenue (ttm)	1.04M
Net Income (ttm)	-109.33M
Shares Out	200.00M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	299,720
Open	29.30
Previous Close	29.10
Day's Range	29.30 - 30.30
52-Week Range	22.20 - 37.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Locus Cell

Locus Cell Co., Ltd. focuses on contract development and manufacturing organization (CDMO) services for cell products in Taiwan and internationally. It offers tissue engineering CDMO services for adipose-derived stem cells, nerve cells, chondrocytes, fibroblasts, epithelial cells, 3D printing cell products, and other cell products; and regenerative medical product CDMO services, such as CAR-T, CAR-NK, iPSC, MSC/ADSC, and other cell types. The company is based in New Taipei City, Taiwan.

• Industry: Commercial Physical and Biological Research
• CEO: Yu-Hsiang Chang
• Employees: 33
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6891

Financial Performance

In 2023, Locus Cell's revenue was 406,000, a decrease of -32.33% compared to the previous year's 600,000. Losses were -96.89 million, 81.2% more than in 2022.